Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Other Working Capital Changes (2017 - 2023)

Exelixis (EXEL) posted quarterly Other Working Capital Changes of $162000.0 for Q2 2023, up 124.47% year-over-year from $72169.6 in Q2 2022, and up 122.91% quarter-over-quarter from -$707000.0 in Q1 2023.

Analysis

Exelixis (EXEL) Other Working Capital Changes (2017 - 2023) Analysis & Trends

Exelixis' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $162000.0 for Q2 2023.

  • In Q2 2023, Other Working Capital Changes rose 124.47% year-over-year to $162000.0; the TTM figure through Jun 2023 stood at -$1.2 million (down 608.28% YoY), while the FY2023 annual figure was -$3.1 million, down 26.46% from the prior year.
  • Other Working Capital Changes for Q2 2023 stood at $162000.0, up from -$707000.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $104.7 million in Q3 2025, with the low at -$94.1 million in Q1 2025.
  • The 5-year median for Other Working Capital Changes is $1.8 million (2023), against an average of $6.0 million.
  • The sharpest annual moves came in 2020 and 2022: Other Working Capital Changes jumped 774.03% in 2020, then sank 162.21% in 2022.
  • Exelixis' Other Working Capital Changes stood at -$1.1 million in 2019, then surged by 931.77% to $8.8 million in 2020, then tumbled by 104.81% to -$426000.0 in 2021, then surged by 251.88% to $647000.0 in 2022, then sank by 74.96% to $162000.0 in 2023.
  • Business Quant data shows EXEL's Other Working Capital Changes at $162000.0 in Q2 2023, -$707000.0 in Q1 2023, and $647000.0 in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 162,000.00
Jun 30, 2023 162,000.00
Mar 31, 2023 -707,000.00
Mar 31, 2023 -707,000.00
Dec 30, 2022 647,000.00
Dec 30, 2022 647,000.00
Sep 30, 2022 -1.30 Mn
Sep 30, 2022 -1.30 Mn
Jul 1, 2022 -662,000.00
Jul 1, 2022 -662,000.00
Apr 1, 2022 -1.17 Mn
Apr 1, 2022 -1.17 Mn
Dec 31, 2021 -426,000.00
Dec 31, 2021 -426,000.00
Oct 1, 2021 2.09 Mn
Oct 1, 2021 2.09 Mn
Jul 2, 2021 -4.08 Mn
Jul 2, 2021 -4.08 Mn
Apr 2, 2021 13.42 Mn
Apr 2, 2021 13.42 Mn